Drug Use-Results Survey of Erbitux (Injection 100 mg) for EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer Patients
Phase 4
- Conditions
- EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer
- Registration Number
- JPRN-UMIN000033658
- Lead Sponsor
- Merck Serono Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1800
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who do not give a full consent to this survey.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method